CHAIR
:
SPEAKER
(S):
Kurt von Emster, Portfolio Manager/General Partner, MPM Capital
Michael Sheffery, PhD, General Partner, Orbimed Advisors, LLC
Robert Forrester, Executive Vice President & Chief Financial Offiicer, CombinatoRx, Inc.
Kris Thiessen, Managing Partner, Helix Management, Inc.
Description
For both public and private companies, hedge funds are an important source of new capital and strong investment community opinion. However, the nature of hedge fund participation can introduce other pressures that biotech management teams need to understand.
Objectives:
Explore how hedge funds can benefit publicly traded R&D-stage companies.
Discuss how private companies evaluate and participate in hedge funds for late-stage financing.
Advise company management on handling participation in a hedge fund.